πŸ‡ΊπŸ‡Έ FDA
Patent

US 7884199

HCV NS3-NS4 protease resistance mutants

granted A61KA61K38/162A61P

Quick answer

US patent 7884199 (HCV NS3-NS4 protease resistance mutants) held by Vertex Pharmaceuticals Incorporated expires Mon Feb 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Feb 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K38/162, A61P, A61P1/16, A61P31/12